No abstract

Intravitreal administration of 1.25 mg bevacizumab at the time of cataract surgery was safe and effective in preventing the progression of DR and diabetic maculopathy in patients with cataract and DR.

Intravitreal injection of 1.25 mg bevacizumab given at the end of vitrectomy appears safe and effective for reducing the incidence of recurrent postoperative vitreous hemorrhage after diabetic vitrectomy. Further randomized studies should be performed to evaluate the potential of this therapy in preventing postoperative recurrent vitreous hemorrhage after diabetic vitrectomy.

Infliximab therapy may be useful in reducing inflammation and leakage from the optic nerve in patients with IRVAN syndrome. This may help preserve or improve visual acuity. However, further studies are required to evaluate the long-term benefits of this therapy.

<H4>BACKGROUND AND OBJECTIVE</H4> <P>To report the efficacy of intravitreal triamcinolone acetonide as an adjuvant in the surgical management of cases with advanced proliferative vitreoretinopathy (PVR).</P> <H4>PATIENTS AND METHODS</H4> <P>Patients with complicated rhegmatogenous retinal detachment and PVR grade C2 or greater were recruited for this interventional, noncomparative, prospective study. All patients underwent three-port pars plana vitrectomy, membrane peeling, laser photocoagulation, and silicone oil injection to reattach the retina followed by 0.1 mL (4 mg) of triamcinolone acetonide injected through the pars plana into the silicone oil. All patients had supplemental laser therapy around retinal breaks and retinectomy edges at 1 to 2 weeks postoperatively.</P> <H4>RESULTS</H4> <P>Patients included 15 males and 9 females, with an average age of 53.6 years (range: 15 to 84 years) and PVR grade C2 to PVR C9. The mean follow-up period was 11.0 months (range: 3 to 26 months). Twenty-one (87.5%) patients had attached retinas at the final followup visit. Visual acuity improved in all patients following surgery (<I>P</I> < .05).</P> <H4>CONCLUSION</H4> <P>Triamcinolone acetonide may have potential as an adjuvant in the treatment of retinal detachment with PVR. Further research is required to evaluate the efficacy of this adjuvant treatment.</P> <P>[<CITE>Ophthalmic Surg Lasers Imaging</CITE> 2007;38:365- 370.]</P> <H4>AUTHORS</H4> <P>From the Cardiff Eye Unit (RAC, AJ, ADL, KL), University Hospital of Wales, Cardiff, United Kingdom; the Department of Ophthalmology and Vision Science (GAP), University of Arizona College of Medicine, Tucson, Arizona; and South Texas Eye Consultants (TF), Corpus Christi, Texas.</P> <P>Accepted for publication November 20, 2006.</P> <P>Address correspondence to Gholam A. Peyman, MD, Department of Ophthalmology and Vision Science, University of Arizona College of Medicine, 655 North Alvernon Way, Suite 108, Tucson, AZ 85711.</P>

No abstract

Aim To evaluate whether Triamcinolone acetonide (TA)-assisted pars plana vitrectomy for visualisation of posterior hyaloid during macular hole surgery has any adverse effects on macular hole closure rate and intraocular pressure (IOP). Methods Case series comparing outcomes and adverse effects in patients who had surgery for macular holes with ILM peel, with and without the use of TA-assisted vitrectomy. Results During the study period, 29 patients had vitrectomy for macular holes. In 18 patients (group 1), TA was used intraoperatively to facilitate visualisation of the posterior hyaloid and in 11 patients (group 2) no TA was used. There was no statistically significant difference in the macular hole closure rates and the improvement in visual acuity between the two groups. No long-term increase in IOP was recorded in any of the 29 patients. The total anatomical success rate in both groups was 85.6% and the average improvement in visual acuity in both groups was two Snellen lines. Conclusions TA is safe and there is no contraindication for its use as an intraoperative aid to facilitate vitreous visualisation in macular hole surgery.

Residual vitreous cortex removal may be beneficial in reducing recurrence of postoperative vitreous hemorrhage following diabetic vitrectomy. Further randomized studies should be performed to evaluate the potential of this surgical technique in preventing postoperative recurrent vitreous hemorrhage following diabetic vitrectomy.